Use to detect the 2019 novel coronavirus (SARS-CoV-2), influenza A/B virus, and RSV virus.
Qualitative Nucleic Acid Amplification
Also acceptable: Oropharyngeal swab, nasal swab.
Refer to the "COVID-19 Specimen Collection Guide" at https://www.aruplab.com/infectious-disease/coronavirus/testing
Nasopharyngeal swab: Place in viral transport media (ARUP supply #12884) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at(800) 522-2787, Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag.
Oropharyngeal or nasal swab: Place in viral transport media (ARUP supply #12884) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787, Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag.
Swabs not in media. Wood swabs, calcium alginate swabs. Media with guanidine-containing materials, 'molecular media' that indicates inactivation of pathogens and preservation of RNA/DNA, charcoal media. Specimens sent in tubes with pop-top lids/caps. Specimens in glass tubes.
Specimen source required.
Swabs: Ambient: Unacceptable; Refrigerated: 2 days; Frozen: 1 month
This test is intended for the qualitative detection and differentiation of 2019 novel coronavirus SARS-CoV-2, influenza A/B virus, and/or RSV virus RNA from individuals suspected of respiratory viral infection.
Not Detected results do not rule out the presence of PCR inhibitors in the patient specimen or assay-specific nucleic acid in concentrations below the level of detection by the assay.
Detected results are indicative of the presence of SARS-CoV-2, influenza A/B, or RSV virus RNA. Due to the complexity of nucleic acid amplification methodologies, there may be a risk of false-positive results. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.
Reliable results are dependent on adequate specimen collection, transport, storage, and handling.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
This test detects and differentiates RNA from 2019 novel coronavirus SARS-CoV-2, influenza A/B virus, and RSV virus. This test does NOT differentiate between influenza A or B.
|Component Test Code*||Component Chart Name||LOINC|
|3003444||Influenza, SARS-CoV-2, and RSV Source||31208-2|
|3003446||Influenza by NAA||62462-7|
|3003447||SARS-CoV-2 by NAA||94500-6|
|3003448||RSV by NAA||40988-8|
- Coronavirus disease - 2019
- COVID-19 Illness
- Influenza A and B
- Respiratory Syncytial Virus, RSV
- RSV Molecular Detection, PCR
- RSV PCR